This observational study will assess the long-term efficacy and safety of MabThera/Rituxan in routine clinical practice in patients with sero-positive rheumatoid arthritis who are non-responders or intolerant to a single tumour necrosis factor (TNF) inhibitor. Data will be collected from each patient over 2 years.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01309282?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
